DIA Biosimilars 2013

University of Cambridge

AstraZeneca inks cancer collaboration

Wednesday, July 10, 2013 12:27 PM

AstraZeneca has entered into an agreement with the University of Cambridge and Cancer Research U.K. for a two-year collaboration on three preclinical and clinical oncology projects. This agreement aims to advance cancer research through the study of tumor mutations and new investigational therapies in prostate, pancreatic and potentially other cancers.

More... »

Cenduit: Now with Patient Reminders

University of Cambridge, Elan launch research center

Monday, November 28, 2011 03:21 PM

The University of Cambridge and Elan have launched The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England. The Cambridge-Elan Centre will provide an interdisciplinary environment uniquely positioned for delivering translational research focused on innovative therapies for Alzheimer's and Parkinson's diseases. This ten-year agreement paves the way for a long-term collaboration between Elan and the University of Cambridge.

More... »

CRF Health – eCOA Forum
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.